Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Actinium Ac 225 FPI-2068

Radiopharmaceutical · Cytotoxic, directed at epidermal growth factor receptor (EGFR) and hepatocyte growth factor receptor (MET) · developed by AstraZeneca

Phase 1 Most advanced trial

AZN Developer

1 Registered trials

What is Actinium Ac 225 FPI-2068?

Actinium Ac 225 FPI-2068 is a radiopharmaceutical composed of a humanized bispecific antibody (FPI-2053) targeting EGFR and c-Met, conjugated to actinium-225. It delivers alpha radiation directly to EGFR- and c-Met-expressing tumor cells, inducing apoptosis and anti-tumor immune responses. It is studied in advanced solid tumors including colorectal, head and neck, lung, pancreatic, gastric, and renal cell carcinomas.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: [225Ac]-FPI-2068
Drug type: Radiopharmaceutical
Targets: epidermal growth factor receptor (EGFR), hepatocyte growth factor receptor (MET)
Mechanism: Cytotoxic, directed at epidermal growth factor receptor (EGFR) and hepatocyte growth factor receptor (MET)
Pathways: apoptosis, anti-tumor immune response
Therapy area: Oncology
Developer: AstraZeneca (AZN)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06147037	Phase 1	Advanced Solid Tumor	Active not recruiting	AZN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Solid TumorGastric CancerHead and Neck Squamous Cell CarcinomaMetastatic Colorectal CarcinomaNon-small Cell Lung CancerPancreatic Ductal AdenocarcinomaRenal Cell Carcinoma

Other drugs acting on EGFR / MET

Neratinib FDA approved Osimertinib FDA approved Telisotuzumab Vedotin FDA approved Tepotinib FDA approved ALX2004 Phase 1 BH-30643 Phase 1/2 CUDC-101 Phase 1 EGFR-TKI inhibitor based on investigator's choice Phase 3 Enozertinib Phase 1/2 Ficerafusp Alfa Phase 2/3 Firmonertinib Phase 3 FPI-2053 Phase 1

More from AstraZeneca

Acalabrutinib FDA approved Anifrolumab FDA approved Benralizumab FDA approved Camizestrant FDA approved Durvalumab FDA approved Olaparib FDA approved Tremelimumab FDA approved Adavosertib Phase 2 AZD0240 Phase 1 AZD4144 Phase 1 AZD4916 Phase 1 AZD5492 Phase 1/2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the AZN page.

Follow AZN, the company behind Actinium Ac 225 FPI-2068

See AZN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AZN catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z